Abstract
Nutlin-3 is a small molecule inhibitor of the MDM2/p53 interaction, which leads to the non-genotoxic p53 stabilization, activation of cell cycle arrest and apoptosis pathways. A series of recent studies have strengthened the concept that selective, non-genotoxic p53 activation by Nutlin-3 might represent an alternative to the current cytotoxic chemotherapy, in particular for pediatric tumors and for hematological malignancies, which retain a high percentage of p53wild-type status at diagnosis. Like most other drugs employed in cancer therapy, it will be unlikely that Nutlin-3 will be used as a monotherapy. In this respect, Nutlin-3 shows a synergistic cytotoxic effect when used in combination with innovative drugs, such as TRAIL or bortozemib. Although Nutlin-3 is currently in phase I clinical trial for the treatment of retinoblastoma, its effects on normal tissues and cell types remain largely to be determined and will require further investigation in the future years.
Keywords: Pediatric malignancies, hematological malignancies, p53 pathway, apoptosis, senescence, therapeutic combinations, Nutlin-3, MDM2, HDM2, PEDIATRIC TUMORS, chemotherapy, malignancies, P-gp, p53-independent, leukemia, synergistic, endothelial, autophagic, pharmacokinetics
Current Pharmaceutical Design
Title: Recent Advances in the Therapeutic Perspectives of Nutlin-3
Volume: 17 Issue: 6
Author(s): Paola Secchiero, Raffaella Bosco, Claudio Celeghini and Giorgio Zauli
Affiliation:
Keywords: Pediatric malignancies, hematological malignancies, p53 pathway, apoptosis, senescence, therapeutic combinations, Nutlin-3, MDM2, HDM2, PEDIATRIC TUMORS, chemotherapy, malignancies, P-gp, p53-independent, leukemia, synergistic, endothelial, autophagic, pharmacokinetics
Abstract: Nutlin-3 is a small molecule inhibitor of the MDM2/p53 interaction, which leads to the non-genotoxic p53 stabilization, activation of cell cycle arrest and apoptosis pathways. A series of recent studies have strengthened the concept that selective, non-genotoxic p53 activation by Nutlin-3 might represent an alternative to the current cytotoxic chemotherapy, in particular for pediatric tumors and for hematological malignancies, which retain a high percentage of p53wild-type status at diagnosis. Like most other drugs employed in cancer therapy, it will be unlikely that Nutlin-3 will be used as a monotherapy. In this respect, Nutlin-3 shows a synergistic cytotoxic effect when used in combination with innovative drugs, such as TRAIL or bortozemib. Although Nutlin-3 is currently in phase I clinical trial for the treatment of retinoblastoma, its effects on normal tissues and cell types remain largely to be determined and will require further investigation in the future years.
Export Options
About this article
Cite this article as:
Secchiero Paola, Bosco Raffaella, Celeghini Claudio and Zauli Giorgio, Recent Advances in the Therapeutic Perspectives of Nutlin-3, Current Pharmaceutical Design 2011; 17 (6) . https://dx.doi.org/10.2174/138161211795222586
DOI https://dx.doi.org/10.2174/138161211795222586 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
“Micromanaging” Glioblastoma Multiforme: The Potential of MicroRNAs, Circular RNAs, and the Hippo Pathway as Novel Treatment Strategies
Current Neurovascular Research The MCM Complex: Its Role in DNA Replication and Implications for Cancer Therapy
Current Cancer Drug Targets Improving Cancer Therapeutics by Molecular Profiling
Current Drug Metabolism The Neurotrophic and Antiangiogenic Functions of PEDF: A Reflection of its Variable Phosphorylation States
Current Genomics From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
Current Neuropharmacology Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment
Current Medicinal Chemistry Chemopreventive Properties of Peptide Lunasin: A Review
Protein & Peptide Letters The Past, Present and Future Subclassification of Patients with Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Morphologic and Molecular Backgrounds for Personalized Management of Genito-Urinary Cancers: An Overview
Current Drug Targets Potential of Photobiomodulation to Induce Differentiation of Adipose- Derived Mesenchymal Stem Cells into Neural Cells
Current Stem Cell Research & Therapy Spinophilin: A New Tumor Suppressor at 17q21
Current Molecular Medicine Genes and Proteins Governing the Cellular Sensitivity to HSP90 Inhibitors: A Mechanistic Perspective
Current Cancer Drug Targets De Novo DNMTs and DNA Methylation: Novel Insights into Disease Pathogenesis and Therapy from Epigenomics
Current Pharmaceutical Design “Virostatics” as a Potential New Class of HIV Drugs
Current Pharmaceutical Design Chalcones Derivatives Acting as Cell Cycle Blockers: Potential Anti Cancer Drugs?
Current Drug Targets Sirtuin Family: A Link to Metabolic Signaling and Senescence
Current Medicinal Chemistry Studies on Anticancer Activities of Lactoferrin and Lactoferricin
Current Protein & Peptide Science Advances in the Development of Non-Human Viral DNA-Vectors for Gene Delivery
Current Gene Therapy Studies of p53 Tumor Suppression Activity in Mouse Models
Current Genomics Polyploidy: The Link Between Senescence and Cancer
Current Pharmaceutical Design